Last reviewed · How we verify
Trivalent sub-unit influenza vaccine
This vaccine stimulates the immune system to produce antibodies and cellular immunity against three strains of influenza virus.
This vaccine stimulates the immune system to produce antibodies and cellular immunity against three strains of influenza virus. Used for Prevention of influenza infection caused by influenza A and B viruses.
At a glance
| Generic name | Trivalent sub-unit influenza vaccine |
|---|---|
| Sponsor | University of Witwatersrand, South Africa |
| Drug class | inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The trivalent sub-unit influenza vaccine contains purified surface antigens (hemagglutinin and neuraminidase) from three influenza virus strains (typically two A strains and one B strain). These non-infectious protein subunits trigger both humoral and cell-mediated immune responses, enabling the body to recognize and neutralize circulating influenza viruses before infection occurs.
Approved indications
- Prevention of influenza infection caused by influenza A and B viruses
Common side effects
- Injection site soreness or erythema
- Myalgia
- Headache
- Low-grade fever
- Fatigue
Key clinical trials
- Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012 (PHASE2)
- Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults (PHASE4)
- Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 Study (PHASE2)
- Immunogenicity and Safety of V70P5 Revaccination Subjects (PHASE3)
- Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2010-2011 (PHASE2)
- Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia (PHASE1, PHASE2)
- Influenza Vaccine in HIV Infected Children (PHASE4)
- Safety and Immunogenicity of One Dose of an Inactivated Trivalent Sub-unit Influenza Vaccine Administered to Non-elderly Adult and Elderly Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: